Ascletis Pharma Inc.
1672
Rankning i aktier
#10386
Ascletis Pharma Inc., a biotechnology company, engages in the research and... Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Aktiekurs
$0.7618007
Marknadsvärde
$799.63M
Förändring (1 dag)
3.93%
Förändring (1 år)
-37.56%
Land
CN
Handel Ascletis Pharma Inc. (1672)
Kategori
Healthcare
Historik för aktiesplit för Ascletis Pharma Inc. (1672)
Aktien Ascletis Pharma Inc. (symbol: 1672) har genomgått totalt 0 aktiesplitar.
Den senaste spliten skedde den Oct 21, 2026.
En 1672-aktie köpt före Oct 21, 2026 motsvarar nu 0 1672-aktier.
Den senaste spliten skedde den Oct 21, 2026.
En 1672-aktie köpt före Oct 21, 2026 motsvarar nu 0 1672-aktier.
Lista över aktiesplitar
| År | Split | Multipel | Kumulativ multipel |
|---|---|---|---|
| Inte tillräckligt med data för de angivna datumen. | |||
Aktiesplitar för liknande företag eller konkurrenter
| Företag | Antal aktiesplitar | Kumulativ multipel | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
